Published : Oct-2017
No. of Pages : 342
1 Table of Contents 2
1.1 List of Tables 8
1.2 List of Figures 15
2 Introduction 16
2.1 Vision Care Devices Overview 16
3 Products under Development 18
3.1 Vision Care Devices - Pipeline Products by Stage of Development 18
3.2 Vision Care Devices - Pipeline Products by Segment 19
3.3 Vision Care Devices - Pipeline Products by Territory 20
3.4 Vision Care Devices - Pipeline Products by Regulatory Path 21
3.5 Vision Care Devices - Pipeline Products by Estimated Approval Date 22
3.6 Vision Care Devices - Ongoing Clinical Trials 23
4 Vision Care Devices - Pipeline Products under Development by Companies 24
4.1 Vision Care Devices Companies - Pipeline Products by Stage of Development 24
4.2 Vision Care Devices - Pipeline Products by Stage of Development 27
5 Vision Care Devices Companies and Product Overview 31
5.1 Acuity Polymers Inc Company Overview 31
5.2 Adventus Technology Inc Company Overview 33
5.3 Aeon Astron Corporation Company Overview 34
5.4 Alcon Laboratories Inc Company Overview 36
5.5 Allotex Inc Company Overview 44
5.6 Apeliotus Ophthalmics (Inactive) Company Overview 45
5.7 Auburn University Company Overview 47
5.8 Axcelon Biopolymers Corp. Company Overview 48
5.9 Bar-Ilan University Company Overview 49
5.10 Bausch & Lomb Inc Company Overview 51
5.11 Bionic Sight LLC Company Overview 55
5.12 Bionic Vision Australia Company Overview 56
5.13 Bionode LLC Company Overview 60
5.14 Children's Hospital Boston Company Overview 61
5.15 Consejo Superior de Investigaciones Cientificas Company Overview 62
5.16 CooperVision Inc Company Overview 63
5.17 Cornea Biosciences Company Overview 68
5.18 DeepOptics Company Overview 69
5.19 eSight Corp Company Overview 70
5.20 Euclid Systems Corp Company Overview 71
5.21 e-Vision Medical Devices, Inc. Company Overview 72
5.22 Eyenovations Company Overview 74
5.23 EyeYon Medical Company Overview 75
5.24 Forschungszentrum Julich GmbH Company Overview 77
5.25 iBionics Inc Company Overview 78
5.26 Imperial College London Company Overview 79
5.27 Institute of Photonic Sciences Company Overview 80
5.28 iSTAR Medical SA Company Overview 81
5.29 John Hopkins University Company Overview 82
5.30 Johnson & Johnson Vision Care Inc Company Overview 83
5.31 Massachusetts Eye and Ear Infirmary Company Overview 85
5.32 McGill University Company Overview 86
5.33 Mercy Research and Development Company Overview 87
5.34 Meta Biomed Co Ltd Company Overview 89
5.35 Microbiosensor Ltd Company Overview 90
5.36 Monash University Company Overview 91
5.37 Nano Retina, Inc. Company Overview 92
5.38 Novartis AG Company Overview 93
5.39 Ocular Dynamics, LLC Company Overview 94
5.40 Ocutec Ltd Company Overview 95
5.41 OPIA Technologies SAS Company Overview 96
5.42 Oxsight Ltd Company Overview 98
5.43 PixelOptics Inc Company Overview 99
5.44 Pixium Vision Company Overview 100
5.45 Presbia Plc Company Overview 106
5.46 Queensland University of Technology Company Overview 110
5.47 Refocus Group Inc Company Overview 111
5.48 RetMap Inc Company Overview 114
5.49 ReVision Optics Inc Company Overview 115
5.50 Royal College of Surgeons in Ireland Company Overview 118
5.51 Stanford University Company Overview 119
5.52 Studio Oculistico Gualdi Company Overview 121
5.53 SynergEyes Inc Company Overview 122
5.54 Tel Aviv University Company Overview 124
5.55 The University of New South Wales Company Overview 125
5.56 The Wilmer Eye Institute at Johns Hopkins Company Overview 126
5.57 UltraVision CLPL Company Overview 127
5.58 University of Auckland Company Overview 128
5.59 University of California Irvine Company Overview 129
5.60 University of California San Diego Company Overview 130
5.61 University of Chicago Medical Center Company Overview 133
5.62 University of Florida Company Overview 134
5.63 University of Illinois at Chicago Company Overview 135
5.64 University of Oxford Company Overview 137
5.65 University of South Florida Company Overview 139
5.66 University of Tennessee Company Overview 140
5.67 University of Tubingen Company Overview 141
5.68 University of Valencia Company Overview 142
5.69 University of Washington Company Overview 144
5.70 Valeant Pharmaceuticals International Inc Company Overview 146
5.71 Va-st Ltd Company Overview 159
5.72 Visioneering Technologies Inc Company Overview 160
5.73 VISTAKON Pharmaceuticals LLC Company Overview 164
5.74 Visus Technology Inc Company Overview 165
5.75 Weill Cornell Medical College Company Overview 166
5.76 Western University Company Overview 168
5.77 Yolia Health Company Overview 169
5.78 ZircLight Inc. Company Overview 170
6 Vision Care Devices - Recent Developments 172
6.1 Sep 15, 2017: Valeant Commits $200,000 to Support Hurricane Relief Efforts 172
6.2 Sep 12, 2017: eSight 3 Launches in Australia and New Zealand 172
6.3 Sep 12, 2017: Essilor Of America Unveils Three Innovative Lens Technologies With The Ultimate Lens Package 172
6.4 Sep 11, 2017: New Data Shows DAILIES TOTAL1 Multifocal Contact Lenses Are Comfortable and Less Dry at the End of the Day 174
6.5 Sep 11, 2017: New Data Shows DAILIES TOTAL1 Multifocal Contact Lenses Are Comfortable and Less Dry at the End of the Day 175
6.6 Sep 08, 2017: Essilor is Gold Sponsor of the 2 nd World Congress of Optometry 176
6.7 Sep 07, 2017: Industry Leader Dr. Doug Benoit Joins VTI as Executive Director of Professional Affairs 176
6.8 Sep 06, 2017: ReVision Optics Names Two Ophthalmic Experts as Medical Monitors to Oversee Raindrop Near Vision Inlay Clinical Performance 177
6.9 Sep 06, 2017: Optometrist Chooses the KAMRA Corneal Inlay for Her Solution to Reading Glasses 178
6.10 Sep 04, 2017: Novartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018. 179
6.11 Aug 31, 2017: The Cooper Companies Announces Third Quarter 2017 Results 180
6.12 Aug 30, 2017: Alcon revamps the packaging for its AIR OPTIX brand monthly replacement contact lenses 181
6.13 Aug 24, 2017: Novartis appoints Bertrand Bodson as Chief Digital Officer 181
6.14 Aug 15, 2017: World's fastest growing IOL Company - Opens Second Manufacturing Facility in Thailand 182
6.15 Aug 14, 2017: TearLab Reports Second Quarter and First Half 2017 Financial Results 183
6.16 Aug 10, 2017: NovaBay Pharmaceuticals Reports Second Quarter 2017 Financial Results 184
6.17 Aug 09, 2017: Bausch + Lomb Receives 510(K) Clearance From FDA for the Therapeutic use of Boston XO Materials 185
6.18 Aug 09, 2017: Bausch + Lomb Receives 510(K) Clearance From FDA for the Therapeutic use of Boston XO2 Materials 186
6.19 Aug 08, 2017: Valeant Announces Second-Quarter 2017 Results 187
6.20 Aug 02, 2017: STAAR Surgical Reports Second Quarter 2017 Results 190
6.21 Aug 02, 2017: Essilor wins Sustainable Business Award for its commitment to the United Nation's Sustainable Development Goals 191
6.22 Aug 01, 2017: Visioneering Technologies Announces Lynn Cali-Cianci As Executive Territory Manager, New York City/Long Island 191
6.23 Jul 28, 2017: Essilor International: Resilient First Half 192
6.24 Jul 28, 2017: Topcon: Notice of Changes of Executive Officers 196
6.25 Jul 27, 2017: Pixium Vision Announces H1 2017 Financial Results and Provides an Update on Its Activities 197
6.26 Jul 27, 2017: Hoya Reports First Quarter Financial Results 199
6.27 Jul 25, 2017: Visioneering Technologies Appoints Lisa Humble as Senior Territory Manager For North and South Carolina 199
6.28 Jul 24, 2017: Antitrust process update for the proposed combination between Essilor and Luxottica 200
6.29 Jul 21, 2017: Sikka Software Wins API World 2017 Award for Health API, Leads the Way in Retail Healthcare Innovation 200
6.30 Jul 20, 2017: Dr. Jim Raulino Joins the VTI Team as Executive Territory Manager for Sacramento and Reno 201
6.31 Jul 18, 2017: Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products 201
6.32 Jul 18, 2017: Visioneering Technologies Appoints Gary Sacks as Executive Territory Manager For New York/Western Massachusetts 207
6.33 Jul 13, 2017: Visioneering Technologies Appoints Michelle Kirst as Territory Manager for New Jersey 207
6.34 Jul 11, 2017: Visioneering Technologies Appoints Ron Makelke as Territory Manager for San Francisco 208
6.35 Jul 10, 2017: NovaBay Pharmaceuticals Announces CFO Transition 208
6.36 Jul 06, 2017: Bausch + Lomb Japan Launches Bausch + Lomb AQUALOX Contact Lenses 209
6.37 Jul 06, 2017: Visioneering Technologies Appoints Carol Baez as Executive Territory Manager for Orange County/San Diego 210
7 Appendix 337
7.1 Methodology 337
7.2 About GlobalData 340
7.3 Contact Us 340
7.4 Disclaimer 340
1.1 List of Tables
Table 1: Vision Care Devices - Pipeline Products by Stage of Development 20
Table 2: Vision Care Devices - Pipeline Products by Segment 21
Table 3: Vision Care Devices - Pipeline Products by Territory 22
Table 4: Vision Care Devices - Pipeline Products by Regulatory Path 23
Table 5: Vision Care Devices - Pipeline Products by Estimated Approval Date 24
Table 6: Vision Care Devices - Ongoing Clinical Trials 25
Table 7: Vision Care Devices Companies - Pipeline Products by Stage of Development 26
Table 8: Vision Care Devices - Pipeline Products by Stage of Development 29
Table 9: Acuity Polymers Inc Pipeline Products & Ongoing Clinical Trials Overview 33
Table 10: Acuity 58 - Product Status 33
Table 11: Acuity 58 - Product Description 33
Table 12: Acuity 85 - Product Status 34
Table 13: Acuity 85 - Product Description 34
Table 14: Adventus Technology Inc Pipeline Products & Ongoing Clinical Trials Overview 35
Table 15: Corneal Onlay - Product Status 35
Table 16: Corneal Onlay - Product Description 35
Table 17: Aeon Astron Corporation Pipeline Products & Ongoing Clinical Trials Overview 36
Table 18: Biolens - Product Status 36
Table 19: Biolens - Product Description 36
Table 20: Contact Lens - Product Status 37
Table 21: Contact Lens - Product Description 37
Table 22: Alcon Laboratories Inc Pipeline Products & Ongoing Clinical Trials Overview 38
Table 23: AIR OPTIX Plus HydraGlyde Monthly Replacement Clear And Color Lens - Product Status 38
Table 24: AIR OPTIX Plus HydraGlyde Monthly Replacement Clear And Color Lens - Product Description 39
Table 25: AIR OPTIX Plus HydraGlyde Monthly Replacement Contact Lenses - Overnight And Flexible Wear - Product Status 39
Table 26: AIR OPTIX Plus HydraGlyde Monthly Replacement Contact Lenses - Overnight And Flexible Wear - Product Description 39
Table 27: Dailies Total 1 Colors SiHy Lens - Product Status 40
Table 28: Dailies Total 1 Colors SiHy Lens - Product Description 40
Table 29: Dailies Total 1 Toric SiHy Lens - Product Status 40
Table 30: Dailies Total 1 Toric SiHy Lens - Product Description 40
Table 31: Smart Contact Lens - Diabetes - Product Status 41
Table 32: Smart Contact Lens - Diabetes - Product Description 41
Table 33: Weekly WG SiHy Lens - Product Status 41
Table 34: Weekly WG SiHy Lens - Product Description 42
Table 35: Alcon Laboratories Inc - Ongoing Clinical Trials Overview 43
Table 36: AIR OPTIX Plus HydraGlyde Monthly Replacement Contact Lenses - Overnight And Flexible Wear - One-month Clinical Comparison of Silicone Hydrogel Monthly Lenses in High Lipid Depositors 44
Table 37: AIR OPTIX Plus HydraGlyde Monthly Replacement Clear And Color Lens - One-month Clinical Comparison of Silicone Hydrogel Monthly Lenses in High Lipid Depositors 45
Table 38: Allotex Inc Pipeline Products & Ongoing Clinical Trials Overview 46
Table 39: Allotex Natural Allograft Lens - Product Status 46
Table 40: Allotex Natural Allograft Lens - Product Description 46
Table 41: Apeliotus Ophthalmics (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 47
Table 42: Comfort Lens - Product Status 47
Table 43: Comfort Lens - Product Description 47
Table 44: Contact Lens - Glaucoma - Product Status 48
Table 45: Contact Lens - Glaucoma - Product Description 48
Table 46: Auburn University Pipeline Products & Ongoing Clinical Trials Overview 49
Table 47: Smart Contact Lenses - Product Status 49
Table 48: Smart Contact Lenses - Product Description 49
Table 49: Axcelon Biopolymers Corp. Pipeline Products & Ongoing Clinical Trials Overview 50
Table 50: MC - PHEMA Based Contact Lens - Product Status 50
Table 51: MC - PHEMA Based Contact Lens - Product Description 50
Table 52: Bar-Ilan University Pipeline Products & Ongoing Clinical Trials Overview 51
Table 53: Bionic Contact Lens - Product Status 51
Table 54: Bionic Contact Lens - Product Description 51
Table 55: Vision Substitution Device - Product Status 52
Table 56: Vision Substitution Device - Product Description 52
Table 57: Bausch & Lomb Inc Pipeline Products & Ongoing Clinical Trials Overview 53
Table 58: Bausch + Lomb ULTRA Astigmatism Contact Lens - Product Status 53
Table 59: Bausch + Lomb ULTRA Astigmatism Contact Lens - Product Description 54
Table 60: Bausch + Lomb ULTRA Presbyopia Contact Lens - Product Status 54
Table 61: Bausch + Lomb ULTRA Presbyopia Contact Lens - Product Description 55
Table 62: Ultra Plus Powers Lens - Product Status 55
Table 63: Ultra Plus Powers Lens - Product Description 56
Table 64: Ultra Toric Lens - Product Status 56
Table 65: Ultra Toric Lens - Product Description 56
Table 66: Bionic Sight LLC Pipeline Products & Ongoing Clinical Trials Overview 57
Table 67: Neuro-Prosthetic Device - Product Status 57
Table 68: Neuro-Prosthetic Device - Product Description 57
Table 69: Bionic Vision Australia Pipeline Products & Ongoing Clinical Trials Overview 58
Table 70: High-Acuity Device With 1024 Electrodes - Product Status 58
Table 71: High-Acuity Device With 1024 Electrodes - Product Description 58
Table 72: High-Acuity Device With 256 Electrodes - Product Status 59
Table 73: High-Acuity Device With 256 Electrodes - Product Description 59
Table 74: Wide-View Device With 24-channel - Product Status 59
Table 75: Wide-View Device With 24-channel - Product Description 60
Table 76: Wide-View Device With 44-channel - Product Status 60
Table 77: Wide-View Device With 44-channel - Product Description 60
Table 78: Wide-View Device With 98 Electrodes - Product Status 61
Table 79: Wide-View Device With 98 Electrodes - Product Description 61
Table 80: Bionode LLC Pipeline Products & Ongoing Clinical Trials Overview 62
Table 81: Contact Lenses - Product Status 62
Table 82: Contact Lenses - Product Description 62
Table 83: Children's Hospital Boston Pipeline Products & Ongoing Clinical Trials Overview 63
Table 84: Contact Lens Drug Delivery Device - Product Status 63
Table 85: Contact Lens Drug Delivery Device - Product Description 63
Table 86: Consejo Superior de Investigaciones Cientificas Pipeline Products & Ongoing Clinical Trials Overview 64
Table 87: Reduced Optical Instrument - Product Status 64
Table 88: Reduced Optical Instrument - Product Description 64
Table 89: CooperVision Inc Pipeline Products & Ongoing Clinical Trials Overview 65
Table 90: Biofinity Energys - Product Status 65
Table 91: Biofinity Energys - Product Description 65
Table 92: MiSight Dual-Focus Myopia Control 1-Day Soft Contact Lens - Product Status 66
Table 93: MiSight Dual-Focus Myopia Control 1-Day Soft Contact Lens - Product Description 66
Table 94: SiH Multifocal - Product Status 66
Table 95: SiH Multifocal - Product Description 67
Table 96: CooperVision Inc - Ongoing Clinical Trials Overview 68
Table 97: MiSight Dual-Focus Myopia Control 1-Day Soft Contact Lens - A Multi-center Dispensing Clinical Evaluation of MiSight Lenses 69
Table 98: MiSight Dual-Focus Myopia Control 1-Day Soft Contact Lens - Efficacy and Safety of MiSight Contact Lenses in Reducing the Progression of Childhood Myopia, Not Pathological, Aged 8-12 Years Randomized Clinical Trial 69
Table 99: Cornea Biosciences Pipeline Products & Ongoing Clinical Trials Overview 70
Table 100: Bioengineered Cornea - Product Status 70
Table 101: Bioengineered Cornea - Product Description 70
Table 102: DeepOptics Pipeline Products & Ongoing Clinical Trials Overview 71
Table 103: Omnifocal Adaptive Lens - Product Status 71
Table 104: Omnifocal Adaptive Lens - Product Description 71
Table 105: eSight Corp Pipeline Products & Ongoing Clinical Trials Overview 72
Table 106: evSpex - Product Status 72
Table 107: evSpex - Product Description 72
Table 108: Euclid Systems Corp Pipeline Products & Ongoing Clinical Trials Overview 73
Table 109: Drug-Eluting Contact Lenses - Product Status 73
Table 110: Drug-Eluting Contact Lenses - Product Description 73
Table 111: e-Vision Medical Devices, Inc. Pipeline Products & Ongoing Clinical Trials Overview 74
Table 112: Electronic Contact Lens - Product Status 74
Table 113: Electronic Contact Lens - Product Description 74
Table 114: Electronic Focusing Eyeglasses - Product Status 75
Table 115: Electronic Focusing Eyeglasses - Product Description 75
Table 116: Eyenovations Pipeline Products & Ongoing Clinical Trials Overview 76
Table 117: Drug Dispensing Contact Lens - Product Status 76
Table 118: Drug Dispensing Contact Lens - Product Description 76
Table 119: EyeYon Medical Pipeline Products & Ongoing Clinical Trials Overview 77
Table 120: DSPEK - Product Status 77
Table 121: DSPEK - Product Description 77
Table 122: Hyper-CL - Drug Delivery - Product Status 78
Table 123: Hyper-CL - Drug Delivery - Product Description 78
Table 124: Forschungszentrum Julich GmbH Pipeline Products & Ongoing Clinical Trials Overview 79
Table 125: Retinal Electrode - Product Status 79
Table 126: Retinal Electrode - Product Description 79
Table 127: iBionics Inc Pipeline Products & Ongoing Clinical Trials Overview 80
Table 128: iBIONICS Diamond Eye - Product Status 80
Table 129: iBIONICS Diamond Eye - Product Description 80
Table 130: Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 81
Table 131: Contact Lens - Product Status 81
Table 132: Contact Lens - Product Description 81
Table 133: Institute of Photonic Sciences Pipeline Products & Ongoing Clinical Trials Overview 82
Table 134: SMARTLENS - Product Status 82
Table 135: SMARTLENS - Product Description 82
Table 136: iSTAR Medical SA Pipeline Products & Ongoing Clinical Trials Overview 83
Table 137: STARvue - Product Status 83
Table 138: STARvue - Product Description 83
Table 139: John Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 84
Table 140: Intra-corneal Implant - Product Status 84
Table 141: Intra-corneal Implant - Product Description 84
Table 142: Johnson & Johnson Vision Care Inc Pipeline Products & Ongoing Clinical Trials Overview 85
Table 143: 1-DAY ACUVUE Multifocal Contact Lens - Product Status 85
Table 144: 1-DAY ACUVUE Multifocal Contact Lens - Product Description 85
Table 145: Anti-allergic Contact Lens - Product Status 86
Table 146: Anti-allergic Contact Lens - Product Description 86
Table 147: Massachusetts Eye and Ear Infirmary Pipeline Products & Ongoing Clinical Trials Overview 87
Table 148: Therapeutic Contact Lens - Product Status 87
Table 149: Therapeutic Contact Lens - Product Description 87
Table 150: McGill University Pipeline Products & Ongoing Clinical Trials Overview 88
Table 151: Portable System - Amblyopia - Product Status 88
Table 152: Portable System - Amblyopia - Product Description 88
Table 153: Mercy Research and Development Pipeline Products & Ongoing Clinical Trials Overview 89
Table 154: First Aid Lens - Product Status 89
Table 155: First Aid Lens - Product Description 89
Table 156: Healing Lens - Product Status 90
Table 157: Healing Lens - Product Description 90
Table 158: Meta Biomed Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 91
Table 159: Artificial Cornea - Product Status 91
Table 160: Artificial Cornea - Product Description 91
1.2 List of Figures
Figure 1: Vision Care Devices - Pipeline Products by Stage of Development 20
Figure 2: Vision Care Devices - Pipeline Products by Segment 21
Figure 3: Vision Care Devices - Pipeline Products by Territory 22
Figure 4: Vision Care Devices - Pipeline Products by Regulatory Path 23
Figure 5: Vision Care Devices - Pipeline Products by Estimated Approval Date 24
Figure 6: Vision Care Devices - Ongoing Clinical Trials 25
